TY - JOUR
T1 - Intra-bone marrow injection of bone marrow and cord blood cells
T2 - An alternative way of transplantation associated with a higher seeding efficiency
AU - Castello, Sandra
AU - Podestà, Marina
AU - Menditto, Vincenzo G.
AU - Ibatici, Adalberto
AU - Pitto, Anna
AU - Figari, Osvaldo
AU - Scarpati, Daniele
AU - Magrassi, Lorenzo
AU - Bacigalupo, Andrea
AU - Piaggio, Giovanna
AU - Frassoni, Francesco
PY - 2004/8
Y1 - 2004/8
N2 - Intravenous (IV) injection is currently the normal method for transplanting hematopoietic cells. However, the problem of seeding efficiency and homing is relevant especially when a limited number of stem cells is available. Intra-bone marrow (IBM) injection of bone marrow cells (BMCs) may overcome this problem.Irradiated (750 cGy) C57BL/6J mice were transplanted with 1 × 10 5 BMCs harvested from transgenic mice expressing an enhanced version of the green fluorescent protein (EGFP +) via IBM or with 1 × 10 6 EGFP + BMCs via IV. Irradiated (320 cGy) NOD/SCID mice were transplanted with 1 × 10 6 human cord blood (CB) cells via IBM or with 1 × 10 7 human CB cells via IV.In C57BL/6J mice after 90 days, the fraction of EGFP + cells harvested was 37% and 53% in IV-treated and IBM-treated (contralateral tibia and femur in the IBM) mice, respectively: the expansion folds were 114 and 1760, respectively. In NOD/SCID mice, the percentages of CD45 + cells and CD45 +/CD34 + cells were, at 30 days, 3.3% and 0.3% in IV-treated mice, and 4.4% and 1.1% in IBM-treated mice. At 60 days, the percentages of CD45 + cells and CD45 +/CD34 + cells were 2.1% and 0.3% in IV-treated mice and 1.4% and 0.4% in IBM-treated mice. At day 90 the percentages of CD45 + cells and CD45 +/CD34 + cells were 3% and 0.3% in IV-treated mice and 2.3% and 0.4% in IBM-treated mice.Our data demonstrate that IBM transplantation is associated with a seeding efficiency 15 times greater than IV transplantation. IBM transplantation may improve the results of transplant and may be useful in several settings: 1) when a limited number of hematopoietic progenitors are available; and 2) in experiments aiming to place in the bone marrow stem cells of other lineages (CNS, muscle, etc.).
AB - Intravenous (IV) injection is currently the normal method for transplanting hematopoietic cells. However, the problem of seeding efficiency and homing is relevant especially when a limited number of stem cells is available. Intra-bone marrow (IBM) injection of bone marrow cells (BMCs) may overcome this problem.Irradiated (750 cGy) C57BL/6J mice were transplanted with 1 × 10 5 BMCs harvested from transgenic mice expressing an enhanced version of the green fluorescent protein (EGFP +) via IBM or with 1 × 10 6 EGFP + BMCs via IV. Irradiated (320 cGy) NOD/SCID mice were transplanted with 1 × 10 6 human cord blood (CB) cells via IBM or with 1 × 10 7 human CB cells via IV.In C57BL/6J mice after 90 days, the fraction of EGFP + cells harvested was 37% and 53% in IV-treated and IBM-treated (contralateral tibia and femur in the IBM) mice, respectively: the expansion folds were 114 and 1760, respectively. In NOD/SCID mice, the percentages of CD45 + cells and CD45 +/CD34 + cells were, at 30 days, 3.3% and 0.3% in IV-treated mice, and 4.4% and 1.1% in IBM-treated mice. At 60 days, the percentages of CD45 + cells and CD45 +/CD34 + cells were 2.1% and 0.3% in IV-treated mice and 1.4% and 0.4% in IBM-treated mice. At day 90 the percentages of CD45 + cells and CD45 +/CD34 + cells were 3% and 0.3% in IV-treated mice and 2.3% and 0.4% in IBM-treated mice.Our data demonstrate that IBM transplantation is associated with a seeding efficiency 15 times greater than IV transplantation. IBM transplantation may improve the results of transplant and may be useful in several settings: 1) when a limited number of hematopoietic progenitors are available; and 2) in experiments aiming to place in the bone marrow stem cells of other lineages (CNS, muscle, etc.).
UR - http://www.scopus.com/inward/record.url?scp=4143092638&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4143092638&partnerID=8YFLogxK
U2 - 10.1016/j.exphem.2004.05.026
DO - 10.1016/j.exphem.2004.05.026
M3 - Article
C2 - 15308330
AN - SCOPUS:4143092638
VL - 32
SP - 782
EP - 787
JO - Experimental Hematology
JF - Experimental Hematology
SN - 0301-472X
IS - 8
ER -